Insider Transactions in Q1 2025 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 29
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
695
-0.48%
|
$20,155
$29.52 P/Share
|
|
Jan 29
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
546
-0.42%
|
$15,834
$29.52 P/Share
|
|
Jan 29
2025
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
695
-0.82%
|
$20,155
$29.52 P/Share
|
|
Jan 29
2025
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
278
-0.5%
|
$8,062
$29.52 P/Share
|
|
Jan 29
2025
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
364
-0.52%
|
$10,556
$29.52 P/Share
|
|
Jan 29
2025
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
825
-0.98%
|
$23,925
$29.52 P/Share
|
|
Jan 29
2025
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
826
-0.07%
|
$23,954
$29.52 P/Share
|
|
Jan 29
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
365
-0.43%
|
$10,585
$29.52 P/Share
|
|
Jan 29
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,824
-0.67%
|
$81,896
$29.52 P/Share
|
|
Jan 22
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
3,323
-2.24%
|
$99,690
$30.43 P/Share
|
|
Jan 22
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,088
-2.33%
|
$92,640
$30.43 P/Share
|
|
Jan 22
2025
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,323
-3.77%
|
$99,690
$30.43 P/Share
|
|
Jan 22
2025
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
3,948
-4.46%
|
$118,440
$30.43 P/Share
|
|
Jan 22
2025
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,948
-0.34%
|
$118,440
$30.43 P/Share
|
|
Jan 22
2025
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,291
-2.27%
|
$38,730
$30.43 P/Share
|
|
Jan 22
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,551
-3.14%
|
$406,530
$30.43 P/Share
|
|
Jan 22
2025
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,751
-2.42%
|
$52,530
$30.43 P/Share
|
|
Jan 22
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,396
-1.62%
|
$41,880
$30.43 P/Share
|
|
Jan 22
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,096
-2.23%
|
$32,880
$30.43 P/Share
|
|
Jan 21
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,929
+25.77%
|
-
|
|
Jan 21
2025
|
David O. Watson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
42,762
+22.38%
|
-
|
|
Jan 21
2025
|
Karen Lewis Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,508
+28.26%
|
-
|
|
Jan 21
2025
|
Nur Nicholson Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,426
+29.17%
|
-
|
|
Jan 21
2025
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,045
+1.29%
|
-
|
|
Jan 21
2025
|
Cedric Francois Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
130,662
+23.22%
|
-
|
|
Jan 21
2025
|
Caroline Baumal Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,594
+29.79%
|
-
|
|
Jan 21
2025
|
James George Chopas VP/Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,591
+20.37%
|
-
|
|
Jan 21
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,508
+24.88%
|
-
|
|
Jan 17
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,730
-1.96%
|
$50,170
$29.96 P/Share
|
|
Jan 17
2025
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,201
-2.44%
|
$63,829
$29.96 P/Share
|
|
Jan 17
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
2,201
-2.04%
|
$63,829
$29.96 P/Share
|
|
Jan 17
2025
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,241
-2.75%
|
$35,989
$29.96 P/Share
|
|
Jan 17
2025
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,145
-3.96%
|
$62,205
$29.96 P/Share
|
|
Jan 17
2025
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
750
-0.07%
|
$21,750
$29.96 P/Share
|
|
Jan 17
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,007
-1.95%
|
$174,203
$29.96 P/Share
|
|
Jan 17
2025
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,853
-3.34%
|
$53,737
$29.96 P/Share
|
|
Jan 17
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
715
-1.91%
|
$20,735
$29.96 P/Share
|
|
Jan 17
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,235
-2.1%
|
$35,815
$29.96 P/Share
|
|
Jan 13
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
4,965
-4.4%
|
$139,020
$28.7 P/Share
|
|
Jan 13
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,170
-2.4%
|
$60,760
$28.7 P/Share
|
|
Jan 13
2025
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,685
-2.89%
|
$75,180
$28.7 P/Share
|
|
Jan 13
2025
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,599
-3.42%
|
$44,772
$28.7 P/Share
|
|
Jan 13
2025
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,632
-4.63%
|
$73,696
$28.7 P/Share
|
|
Jan 13
2025
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
264
-0.46%
|
$7,392
$28.7 P/Share
|
|
Jan 13
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,247
-1.99%
|
$174,916
$28.7 P/Share
|
|
Jan 13
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,599
-2.65%
|
$44,772
$28.7 P/Share
|
|
Jan 13
2025
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,288
-0.2%
|
$64,064
$28.7 P/Share
|
|
Jan 13
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
783
-2.05%
|
$21,924
$28.7 P/Share
|
|
Jan 08
2025
|
Keli Walbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,090
+50.0%
|
-
|
|
Jan 06
2025
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,816
-4.82%
|
$92,928
$33.81 P/Share
|